Objectives-To assess performance of shear wave elastography for evaluation of fibrosis and the histologic stage in patients with autoimmune liver disease (ALD) and to validate previously established advanced fibrosis cutoff values in this cohort.
A utoimmune liver disease (ALD) includes a number of diseases: autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and the "overlap" syndromes in which more than 1 of these conditions is present. 1 Autoimmune hepatitis is a chronic type of hepatitis characterized by interface hepatitis, hypergammaglobulinemia, and autoantibodies. It affects patients of all ages and is associated with substantial morbidity and mortality if not properly treated. [2] [3] [4] Primary biliary cirrhosis is a chronic cholestatic liver disease characterized by the progressive destruction of the intrahepatic bile ducts. 5 It most often affects middle-aged women. 1 Primary sclerosing cholangitis is a cholestatic liver disease characterized by stricturing of larger intrahepatic or extrahepatic bile ducts. Among the overlap syndromes, AIH-PBC overlap syndrome is the most common. These diseases share a common progression pathway. 6 Without timely and appropriate intervention, fibrosis may progress to cirrhosis, with an elevated risk of hepatocellular carcinoma and, ultimately, liver failure. 7 The goal of management in these conditions is to prevent disease progression to irreversible liver failure. 8 Early detection and staging of fibrosis are helpful for risk stratification and evaluating the therapeutic response. Therefore, the identification and classification of the stage of liver fibrosis are of value in the treatment of patients with ALD.
Nonfocal liver biopsy is considered the reference standard for evaluating hepatic fibrosis. 9 However, liver biopsy is both invasive and expensive. In addition, it is susceptible to sampling errors as well as interobserver and intraobserver variability in fibrosis staging. [10] [11] [12] Therefore, alternative noninvasive methods for diagnosing and stage liver fibrosis have been sought. 13 Surrogate imaging techniques and blood markers have been shown to have varying accuracies in predicting liver fibrosis. 8 A variety of imaging techniques have been applied, including morphologic analysis, computed tomographic perfusion, magnetic resonance perfusion, diffusion-weighted imaging, and magnetic resonance elastography. [14] [15] [16] [17] Recent studies have investigated the utility of transient elastography and magnetic resonance elastography in patients with AIH. [18] [19] [20] Advances in ultrasound (US) technology have enabled noninvasive and quantitative measurements of liver stiffness with various US-based elastographic methods, including transient elastography, acoustic radiation force impulse imaging, and shear wave elastography (SWE). Both transient elastography and acoustic radiation force impulse imaging have been evaluated in several studies for their roles in staging liver fibrosis and have shown high accuracy for the diagnosis of cirrhosis and intermediate accuracy for differentiation between mild and moderate liver fibrosis. [21] [22] [23] Shear wave elastography is a new real-time technique using measurements of acoustically generated tissue shear wave propagation speeds to derive liver stiffness estimates. This technique has been applied in the diagnosis of liver fibrosis in chronic liver disease caused by hepatitis virus B or C and in those with alcoholic liver disease or nonalcoholic fatty liver disease. 8, 24, 25 In a previous study, we reported that a threshold value of 7.29 kPa differentiated METAVIR stage F2 or higher from F0 and F1 in patients with chronic liver disease with sensitivity and specificity of 91.4% and 52.5%, respectively. 8 The aims of this study were to assess the performance of SWE in the evaluation of fibrosis in patients with ALD and to validate previously established estimated tissue Young modulus cutoff values for fibrosis in this cohort of patients.
Materials and Methods

Design Overview and Study Population
This pilot study was approved by the Institutional Review Board and compliant with the Health Insurance Portability and Accountability Act. Patients with known or suspected ALD on the basis of biochemical, serologic, or radiologic findings and scheduled for a US-guided nonfocal liver biopsy were eligible. Patients younger than 18 years and those who had transplantations were excluded. The Institutional Review Board waived the requirement to obtain informed consent for this study. All patients underwent an SWE examination performed by a single sonographer with 16 years of experience in assisting biopsy procedures in the interventional radiology US suite. This sonographer also had more than 5 years of experience in performing SWE. Nonfocal liver biopsies were subsequently performed under US guidance.
Shear Wave Elastography
Shear wave elastography was performed with an Aixplorer US system (SuperSonic Imagine, Aix-enProvence, France) equipped with a convex broadband transducer (SC6-1). The technology measures the propagation velocity of acoustically generated tissue shear waves to estimate liver stiffness, expressed in kilopascals, and termed the Young modulus. The Aixplorer provides anatomic B-mode US images and elastographic color maps simultaneously, permitting selection of specific regions of liver parenchyma free of blood vessels or lesions for analysis. Shear wave elastographic measurements were obtained in the upper right hepatic lobe at the end of normal expiration via an intercostal acoustic window. By protocol, the SWE region of interest was placed at a depth of less than 6 cm from the skin surface and at least 1 cm deep to the liver capsule. Shear wave elastographic measurements were recorded only when the region of interest (with fixed dimension of 10 3 10 mm) was filled with color. Only regions that avoided blood vessels and portal tracts were used. Most examinations comprised 10 sequential measurements. In some cases, fewer measurements were made. If fewer than 8 measurements were made, the case was excluded from this study. The median value of the measurements was used for the analysis.
Shear Wave Elastographic Image Review
A review of all SWE images was performed by a research fellow (M.D.) with 3 years of elastography experience. The exclusion criteria for the SWE images were as follows: (1) if a minimum of 8 measurements was not obtained; (2) the region of interest had poor color fillin; (3) the region of interest was placed just below the liver capsule or greater than 5 cm from the skin.
Liver Biopsy
Nonfocal liver biopsy was performed under US guidance in the Interventional Radiology Department of our hospital. Patients gave biopsy consent and were given local anesthesia and conscious sedation before the procedure. All liver biopsy specimens were obtained from the upper right lobe by using a 16-gauge biopsy instrument (BioPince; Medical Device Technologies, Inc, Gainesville, FL). All specimens were fixed in formalin and then embedded in paraffin.
Histologic Examination
The liver biopsy specimens were reviewed by a single subspecialist pathologist (A.K.B.) with 29 years of experience, who was blinded to the clinical information and estimated tissue Young modulus. The length of each Data are presented as mean 6 SD where applicable.
Li et al-Shear Wave Elastography in Autoimmune Liver Disease specimen and the number of portal tracts visualized were recorded. A biopsy sample at least 1 cm long with visualization of a minimum of 3 portal triads was considered adequate for the histologic examination. The METAVIR staging system was used to stage liver fibrosis and calculate the necroinflammation scores. 26 In the METAVIR system, fibrosis is graded on a 5-point ordinal scale from 0 to 4: (F0, no fibrosis; F1, enlarged fibrotic portal tract; F2, few portal-portal septa but intact architecture; F3, numerous septa with architectural distortion but no obvious cirrhosis; and F4, cirrhosis). The necroinflammatory score was calculated based on the scores of piecemeal or interface hepatitis (score 0-3) and lobular hepatitis (score 0-2) to provide a total necroinflammatory activity score of 0 to 3 (also classified as A0-A3). 26 Steatosis was independently classified as S0 (absent), S1 (<5%), S2 (5%-33%), S3 (34%-66%), and S4 (>66%). Independent of the research pathologic interpretation and reporting, clinical notes were reviewed, and the clinically reported PBC staging system, which was classified as S0 (normal), S1 (portal stage), S2 (periportal stage), S3 (septal stage), and S4 (biliary cirrhosis), was recorded when available.
Statistical Analyses
All statistical analyses were performed with SPSS version 23.0 software (IBM Corporation, Armonk, NY). Data were expressed as mean 6 standard deviation. The Kendall s-b correlation test was performed to identify the correlation between the estimated tissue Young modulus and fibrosis, steatosis, and the METAVIR necroinflammatory score. The Spearman correlation test was performed to identify the correlation between the estimated tissue Young modulus and clinical data. The diagnostic performance of SWE in differentiating substantial fibrosis (F2) from lower fibrosis stages (F0 and F1) was evaluated by a receiver operating characteristic (ROC) curve analysis. The area under the receiver operating characteristic curve (AUROC) was calculated. A mathematically optimal cutoff value (by maximizing the Youden index) was computed by an online generator (http://vassarstats.net/clin1.html) to report the point sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (LR), and negative LR. Confidence intervals (CIs) were calculated by an online CI generator (https://www2. ccrb.cuhk.edu.hk/stat/confidence%20interval/Diagnostic% 20Statistic.htm). P < .05 was considered statistically significant.
Results
According to the histologic results, patients with other diffuse liver diseases such as hepatitis C viral disease, hepatitis B viral disease, nonalcoholic fatty liver disease, and alcoholic liver disease were excluded from this study. A total of 51 patients (11 women and 40 men; mean age, 50.80 6 15.21 years) with autoimmune disease (PBC, n 5 24; AIH, n 5 20; PSC, n 5 4; and overlap syndrome, n 5 3) were enrolled and analyzed ( Figure  1 ). The indication for liver biopsy was for follow-up of known ALD in 64.7% of patients (n 5 33) and for tissue diagnosis in 35.3% of patients (n 5 18; Table 1 ). Based on the results of pathologic examinations, 6 patients had no fibrosis; 27 patients had F1 fibrosis; 9 patients had F2 fibrosis; and 9 patients had F3 fibrosis. No patient had F4 fibrosis. Table 2 ). According to the Kendall s-b correlation analysis, the fibrosis stage and necroinflammation score were moderately correlated with the estimated tissue Young modulus (r 5 0.386; P < .001; r 5 0.338; P 5 .002, respectively). The PBC stage was also moderately correlated with the estimated tissue Young modulus (r 5 0.482; P 5 .003). Steatosis did not correlate with the estimated tissue Young modulus (r 5 -0.066; P 5 .551). These parameters are summarized in Table 3 .
The correlations between the clinical data of enrolled patients and estimated tissue Young modulus were also calculated. According to the results of the Spearman correlation analysis, for all of the included patients, the values of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin had positive correlations with the estimated tissue Young modulus (r 5 0.501; P < .001; r 5 0.44; P 5 .001; r 5 0.291; P 5 .038), whereas the serum albumin value was negatively correlated with the estimated tissue Young modulus (r 5 20.309; P 5 .033). In patients with PBC, AST and ALT values were positively correlated with the estimated tissue Young modulus (r 5 0.473; P 5 .020; r 5 0.413; P 5 .045). For patients with AIH, the values of AST, ALT, alkaline phosphatase (ALP), and total bilirubin were positively correlated with the estimated tissue Young modulus (r 5 0.579; P 5 .008; r 5 0.489; P 5 .029; r 5 0.600; P 5 .005; r 5 0.519; P 5 .019). These results are summarized in Table 4 .
The ROC analysis of the ability of SWE to differentiate higher stages of fibrosis (F2) from lower stages of fibrosis (F0 and F1; Figure 2 ) yielded an AUROC of 0.781 (95% CI, 0.641-0.921). A mathematically optimal cutoff value of 9.15 kPa was obtained on the basis of the ROC curve, yielding 83.3% sensitivity and 72.7% specificity (Table 5 ). Figure 2 . Receiver operating characteristic curve for differentiation of fibrosis stage F2 or higher from stages F0 and F1.
We divided the patients into 2 subgroups based on biopsy indication: patients following known liver disease and patients undergoing initial diagnosis. The cutoff value of 9.15 kPa provided sensitivity of 84.6% and specificity of 75% in the follow-up group and sensitivity of 80.0% and specificity of 69.2% in the initial diagnosis group (Table 6) .
In a prior study, we reported a cutoff value of 7.29 kPa to differentiate fibrosis stages F2 from F0 and F1 in patients with chronic liver disease, with sensitivity and specificity of 91.4% and 52.5%, respectively. 8 In this new patient cohort, our previously established cutoff value yielded comparable sensitivity of 88.9% and specificity of 39.4% for the ALD group as a whole (Table 7) . We also determined the diagnostic performance of this previously established cutoff value in the subgroups of patients with PBC and AIH ( Table 7) .
Discussion
Autoimmune liver disease treatment and the prognosis depend on the disease stage. Given the risks and limitations of percutaneous liver biopsy, surrogate techniques, including imaging and serum markers, are being developed and examined for noninvasive assessment of ALD stages. 27, 28 Shear wave elastography is a promising US technique that has the potential to provide noninvasive and quantitative assessments of tissue stiffness. Previous studies have evaluated the diagnostic performance of SWE for liver fibrosis estimation in patients with chronic hepatitis C and chronic hepatitis B. 24, 25, 29 Those studies suggest that SWE has the potential to measure hepatic fibrosis noninvasively and accurately. We aimed to assess SWE for fibrosis staging in patients with ALD.
Our results indicate a moderate correlation between the fibrosis stage, necroinflammation score, PBC stage, and estimated tissue Young modulus (r 5 0.386; P < .001; r 5 0.338; P 5 .002; r 5 0.482; P 5 .003, respectively). These results are consistent with our prior study and the findings of other investigators. 30, 31 Similarly, the lack of a correlation with steatosis is concordant with the literature. [32] [33] [34] Some serum markers have been proposed as alternatives to liver biopsy for the evaluation of fibrosis in chronic liver disease. The serum total bilirubin level, serum albumin level, ALP level, and platelet count have been reported to be individually linked with survival in patients with PSC. 35, 36 In our study, AST, ALT, and total bilirubin values were positively correlated with the estimated tissue Young modulus for all patients, whereas the serum albumin values was negatively correlated. Not surprisingly, serum autoantibodies were not significantly correlated with the estimated tissue Young modulus; their presence is neither necessary for the diagnosis of ALD, nor are they of prognostic value. 37 Our previous study reported sensitivity of 91.4% and specificity of 52.5% for the differentiation of F2 or higher from lower fibrosis stages in a group of patients with a variety of chronic liver diseases at a cutoff value of 7.29 kPa. 8 We assessed this cutoff value in this study and obtained sensitivity of 88.9% and specificity of 39.4%, with a corresponding PPV and NPV of 44.4% and 86.7%, respectively. For the subgroup with PBC, the sensitivity, specificity, PPV, and NPV were 87.5%, 43.8%, 43.8%, and 87.5%. For the subgroup with AIH, the sensitivity, specificity, PPV, and NPV were 85.7%, 38.5%, 42.9%, and 83.3%. Although these values are comparable, they are also different, suggesting that underlying disease processes may differ in optimal SWE threshold values for fibrosis staging.
There were some limitations to our study, including the use of the METAVIR system to stage liver fibrosis. This system, although widely used for histologic evaluation of hepatic fibrosis, was based on patients with chronic viral hepatitis, and its applicability to other disease processes is not known. Second, only 51 patients were included in our study because ALD is a set of rare diseases, and the incidence is very low. Consequently, a larger series of patients can be reasonably expected in a future study. No patients in this study had F4 fibrosis (ie, cirrhosis), and the proportion of patients with advanced fibrosis is smaller than that of patients with early fibrosis. Most our patients were white. It is not clear whether people of different races have any differences in liver stiffness. Finally, in our study, only a small subset of the group had PSC or overlap syndrome compared with PBC and AIH.
Our study suggests that SWE may be useful for liver fibrosis staging in patients with ALD. However, larger studies are needed to validate these results and assist with computing optimal estimated Young modulus cutoff values in these patients.
